Cancer is one of the leading causes of mortality and morbidity worldwide. None included the perspective of other agents, that may have some influence in the decision-making process and that also represent the interests of the society as a whole.
None included the perspective of other agents, that may have some influence in the decision-making process and that also represent the interests of the society as a whole. 
BACKGROUND

Study participants
METHODS
Oncologists and health policy makers were identified amongst hospital departments and national health organizations web sites directories.
A total of 425 oncologists, 140 health policy makers, 210 patients and 420 individuals from the general population were invited to participate.
Contact with patients was made through local cancer associations and the Spanish cancer federation.
For the general population, a convenience sample was used. Employees in technological companies, research institutes, universities and governmental institutions were invited to take part in the study, assuring that participants were able to understand the questionnaire.
Electronic questionnaire
METHODS
Life prolonging
Imagine that a new treatment for lung metastasis has an additional cost of €50,000 per year compared to standard treatment, having both of them the same safety profile. Standard treatment would provide a 1-year survival without changing the health related quality of life. Indicate the minimum survival benefit that the new treatment should provide in order to be funded by the National Health System. 
STANDARD TREATMENT
RESULTS
Sociodemographic characteristics
Life prolonging
RESULTS
STANDARD TREATMENT
Cost: €25, 
ICER =
Oncologists were the ones that valued the most the gains in survival
